• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Vapotherm Inc. (Amendment)

    2/14/24 6:06:05 AM ET
    $VAPO
    Medical/Dental Instruments
    Health Care
    Get the next $VAPO alert in real time by email
    SC 13G/A 1 formsc13ga.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, DC 20549

     

    SCHEDULE 13G

     

    Under the Securities Exchange Act of 1934 (Amendment No. __2__)*

     

    Vapotherm, Inc.

    (Name of Issuer)

     

    Common Stock, par value $0.001 per share

    (Title of Class of Securities)

     

    922107107

    (CUSIP Number)

     

    December 31, 2023

    (Date of Event Which Requires Filing of this Statement)

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☐ Rule 13d-1(b)
      ☒ Rule 13d-1(c)
      ☐ Rule 13d-1(d)

     

     

    *The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

     

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     

     
    CUSIP No.: 922107107

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Crow’s Nest Holdings LP
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
      (a) ☐
      (b) ☒
       
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
      561,001*
       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
      561,001*
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      561,001*
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      ☐
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      9.14%*
       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      IA

     

     
    CUSIP No.: 922107107

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Crow’s Nest Holdings Master Fund LP
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
      (a) ☐
      (b) ☒
       
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Cayman Islands
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
      561,001*
       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
      561,001*
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      561,001*
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      ☐
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      9.14%*
       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      PN

     

     
    CUSIP No.: 922107107

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      Crow’s Nest GP LLC
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
      (a) ☐
      (b) ☒
       
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      Delaware
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
      561,001*
       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
      561,001*
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      561,001*
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      ☐
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      9.14%*
       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC

     

     
    CUSIP No.: 922107107

     

    1. NAME OF REPORTING PERSONS
      I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
       
      John A Carrington
       
    2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (SEE INSTRUCTIONS)
       
      (a) ☐
      (b) ☒
       
    3. SEC USE ONLY
       
       
    4. CITIZENSHIP OR PLACE OF ORGANIZATION
       
      United States
       
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
       
    5. SOLE VOTING POWER
       
      0
       
    6. SHARED VOTING POWER
       
      561,001*
       
    7. SOLE DISPOSITIVE POWER
       
      0
       
    8. SHARED DISPOSITIVE POWER
       
      561,001*
       
    9. AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
       
      561,001*
       
    10. CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
       
      ☐
       
    11. PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
       
      9.14%*
       
    12. TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
       
      HC, IN

     

     
    CUSIP No.: 922107107

     

    Item 1. (a). Name of Issuer:
         
        Vapotherm, Inc.
         
      (b). Address of issuer’s principal executive offices:
         
        100 Domain Drive
        Exeter, NH 03833
         
    Item 2. (a). Name of person filing:
         
        Crow’s Nest Holdings LP*
        Crow’s Nest Holdings Master Fund LP*
        Crow’s Nest GP LLC*
        John A. Carrington*
         
      (b). Address or principal business office or, if none, residence:
         
        c/o Crow’s Nest Holdings LP
        5820 Patterson Ave, Suite 202
        Richmond, VA 23226
         
      (c). Citizenship:
         
        Crow’s Nest Holdings LP - Delaware
        Crow’s Nest Holdings Master Fund LP – Cayman Islands
       

    Crow’s Nest GP LLC- Delaware

    John A. Carrington- United States

         
      (d). Title of class of securities:
         
        Common Stock, par value $0.001 per share
         
      (e). CUSIP No.:
         
        922107107

     

     
    CUSIP No.: 922107107

     

    Item 3. If This Statement is filed pursuant to §§.240.13d-1(b) or 240.13d-2(b), or (c), check whether the person filing is a
       
      N/A
       
    Item 4. Ownership.
       
      Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

     

      (a) Amount beneficially owned:
         
        Crow’s Nest Holdings LP– 561,001*
        Crow’s Nest Holdings Master Fund LP – 561,001*
        Crow’s Nest GP LLC – 561,001*
        John A. Carrington – 561,001*
         
      (b) Percent of class:
         
        Crow’s Nest Holdings LP– 9.14%*
        Crow’s Nest Holdings Master Fund LP – 9.14%*
        Crow’s Nest GP LLC – 9.14%*
        John A. Carrington – 9.14%*
         
      (c) Number of shares as to which the person has:
         
        (i) Sole power to vote or to direct the vote
           
          Crow’s Nest Holdings LP– 0
          Crow’s Nest Holdings Master Fund LP - 0
          Crow’s Nest GP LLC – 0
          John A. Carrington – 0
           
        (ii) Shared power to vote or to direct the vote
           
          Crow’s Nest Holdings LP– 561,001*
          Crow’s Nest Holdings Master Fund LP – 561,001*
          Crow’s Nest GP LLC – 561,001*
          John A. Carrington – 561,001*
           
        (iii) Sole power to dispose or to direct the disposition of
           
          Crow’s Nest Holdings LP– 0
          Crow’s Nest Holdings Master Fund LP - 0
          Crow’s Nest GP LLC – 0
          John A. Carrington – 0
           
        (iv) Shared power to dispose or to direct the disposition of
           
          Crow’s Nest Holdings LP– 561,001*
          Crow’s Nest Holdings Master Fund LP – 561,001*
          Crow’s Nest GP LLC – 561,001*
          John A. Carrington– 561,001*

     

    * The common stock (the “Shares”) reported herein are held by Crow’s Nest Holdings Master Fund LP (“Crow’s Nest Master”) managed by Crow’s Nest Holdings LP (“Crow’s Nest”) in its capacity as investment manager. Crow’s Nest GP LLC serves as a general partner of Crow’s Nest Master and is beneficially owned by John Carrington. Mr. Carrington is the managing member of Crow’s Nest GP LLC. The Shares reported herein for Crow’s Nest GP LLC and Mr. Carrington represent the above referenced Shares reported with respect to Crow’s Nest Master. Each of the Reporting Persons disclaims beneficial ownership of the shares reported herein except to the extent of its or his pecuniary interest therein. The percentages reported herein are calculated based upon the statement in the Issuer’s Report on Form 10-Q for the period ended September 30, 2023, as filed with the Securities and Exchange Commission on November 8, 2023, that there were 6,138,333 Shares of the Issuer outstanding as of November 2, 2023.

     

    In addition to the Shares reported herein by the Reporting Persons, Crow’s Nest Master holds certain warrants subject to a contractual blocker, which prohibits the Reporting Persons from exercising or converting such securities to the extent that, upon such exercise or conversion, the Reporting Persons would collectively beneficially own in excess of 9.99% of the Shares outstanding as a result of the conversion or exercise.

     

     
    CUSIP No.: 922107107

     

    Item 5. Ownership of Five Percent or Less of a Class.
       
      If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following.
       
      N/A
       
    Item 6. Ownership of More Than Five Percent on Behalf of Another Person.
       
      If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.
       
      N/A
       
    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
       
      If a parent holding company or control person has filed this schedule, pursuant to Rule 13d-1(b)(1)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company or control person has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary.
       
      N/A
       
    Item 8. Identification and Classification of Members of the Group.
       
      If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(J), so indicate under Item 3(j) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identity of each member of the group.
       
      N/A
       
    Item 9. Notice of Dissolution of Group.
       
      Notice of dissolution of a group may be furnished as an exhibit stating the date of the dissolution and that all further filings with respect to transactions in the security reported on will be filed, if required, by members of the group, in their individual capacity. See Item 5.
       
      N/A
       
    Item 10. Certification.
       
      By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.

     

     
    CUSIP No.: 922107107

     

    SIGNATURE

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated: February 14, 2024  
      Crow’s Nest Holdings LP
       
      By: Crow’s Nest Holdings GP LLC, its General partner
         
      By: /s/ John A. Carrington
        John A. Carrington, Managing Member
         
      Crow’s Nest Holdings Master Fund LP
         
      By: Crow’s Nest Holdings LP, its Investment Manager
      By: Crow’s Nest Holdings GP LLC, the General Partner of the Investment Manager
         
      By: /s/ John A. Carrington
        John A. Carrington, Managing Member
         
      Crow’s Nest GP LLC
         
      By: /s/ John A. Carrington
        John A. Carrington, Managing Member
         
      John A. Carrington
         
      By:  /s/ John A. Carrington
        John A. Carrington, Individually

     

    The original statement shall be signed by each person on whose behalf the statement is filed or his authorized representative. If the statement is signed on behalf of a person by his authorized representative other than an executive officer or general partner of the filing person, evidence of the representative’s authority to sign on behalf of such person shall be filed with the statement, provided, however, that a power of attorney for this purpose which is already on file with the Commission may be incorporated by reference. The name and any title of each person who signs the statement shall be typed or printed beneath his signature.

     

    Note. Schedules filed in paper format shall include a signed original and five copies of the schedule, including all exhibits. See s.240.13d-7 for other parties for whom copies are to be sent.

     

    Attention. Intentional misstatements or omissions of fact constitute Federal criminal violations (see 18 U.S.C. 1001).

     

     

    Get the next $VAPO alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $VAPO

    DatePrice TargetRatingAnalyst
    5/6/2022$12.00 → $5.00Buy → Hold
    Canaccord Genuity
    4/7/2022$23.00 → $8.00Overweight → Underweight
    Piper Sandler
    More analyst ratings

    $VAPO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Vapotherm Announces Closing of Merger

      EXETER, N.H., Sept. 20, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has closed its merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC. On June 17, 2024, the Company announced that it had signed a definitive agreement and plan of merger with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund. Concurrently with the entry into the definitive agreem

      9/20/24 10:33:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports Second Quarter 2024 Financial Results

      EXETER, N.H., Aug. 12, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), today announced second quarter 2024 financial results and related highlights. Second Quarter 2024 Financial Results and Related Highlights Net revenue for the second quarter of 2024 was $16.9 million, an increase of 5.3% as compared to the second quarter of 2023Disposables revenue increased by 13.9% as compared to the second quarter of 2023U.S. disposables revenue increased by 25.9% as compared to the second quarter of 2023Gross margin in the second quarter of 2024 was 49.

      8/12/24 5:15:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Enters Into Definitive Merger Agreement; Transaction Would Result In Company Going Private

      EXETER, N.H., June 17, 2024 /PRNewswire/ -- Vapotherm, Inc. (OTCQX:VAPO), ("Vapotherm" or the "Company"), announced today that it has signed a definitive merger agreement with a newly-formed entity organized and funded by an affiliate of Perceptive Advisors, LLC, a leading health care investment firm ("Perceptive"), and its Perceptive Discovery Fund.  Concurrently with the entry into the definitive merger agreement, our existing lender, investment affiliates managed by SLR Capital Partners ("SLR") have agreed to convert approximately $81.0 million of term debt into preferred equity of the newly-formed entity, and Perceptive will invest $50.0 million of new preferred equity capital into the b

      6/17/24 6:55:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Leadership Updates

    Live Leadership Updates

    See more
    • Perimeter Medical Imaging AI Strengthens Leadership Team with Appointment of Experienced MedTech Executive, Adam Hodges, as Vice President, Sales and Marketing

      TORONTO and DALLAS, Sept. 8, 2023 /PRNewswire/ - Perimeter Medical Imaging AI, Inc. (TSXV: PINK) (OTC: PYNKF) (FSE: 4PC) ("Perimeter" or the "Company") – a commercial-stage medical technology company – today announced the appointment of experienced medtech sales executive, Adam Hodges, as its Vice President, Sales and Marketing, effective immediately. Adrian Mendes, Perimeter's Chief Executive Officer stated, "I am excited to welcome Adam to the Perimeter team as our senior leader responsible for the strategy and execution of our sales-related goals. Adam's extensive medtech b

      9/8/23 8:30:00 AM ET
      $IART
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Eargo Announces Strategic Additions to Board of Directors Following Patient Square Capital Becoming New Majority Shareholder

      SAN JOSE, Calif., Dec. 07, 2022 (GLOBE NEWSWIRE) -- Eargo, Inc. ("Eargo" or the "Company") (NASDAQ:EAR), a medical device company on a mission to improve the quality of life for people with hearing loss, today announced the appointments of several new directors following the closing of the Company's rights offering as previously announced on November 29, 2022. Patient Square Capital became the Company's majority owner upon closing of the rights offering and conversion of Patient Square's senior secured convertible notes per its investment in June 2022. As previously announced, following the completion of the rights offering, Patient Square has the right to nominate a number of directors t

      12/7/22 4:05:00 PM ET
      $EAR
      $ITGR
      $VAPO
      Medical Specialities
      Health Care
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Medical/Dental Instruments

    $VAPO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Arnerich Anthony L. returned $344,305 worth of shares to the company (232,993 units at $1.48), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 5:01:08 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • President and CEO Army Joseph returned $43,419 worth of shares to the company (452,698 units at $0.10), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:43:19 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SVP & Chief Financial Officer Landry John returned $51,982 worth of shares to the company (71,661 units at $0.73), closing all direct ownership in the company (SEC Form 4)

      4 - VAPOTHERM INC (0001253176) (Issuer)

      9/24/24 4:14:26 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Vapotherm Inc.

      15-12G - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 11:32:00 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:03 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form EFFECT filed by Vapotherm Inc.

      EFFECT - VAPOTHERM INC (0001253176) (Filer)

      9/25/24 12:15:04 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Arnerich Anthony L. bought $117,337 worth of shares (37,750 units at $3.11), increasing direct ownership by 263% to 24,509 units (SEC Form 4) (Amendment)

      4/A - VAPOTHERM INC (0001253176) (Issuer)

      10/4/23 4:11:34 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Financials

    Live finance-specific insights

    See more
    • Vapotherm To Report Second Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the second quarter of 2023 after the close of trading on Tuesday, August 8, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors

      7/25/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm Reports First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced first quarter 2023 financial results. First Quarter 2023 Summary and Highlights Total revenue for the first quarter of 2023 was $17.7 million Capital revenue increased by 28% as compared to the fourth quarter of 2022 due to strong HVT 2.0 sales Disposables revenue decreased by 12% as compared to the fourth quarter of 2022 due to the timing of the US flu season Gross margin in the first quarter of 2023 was 35.0% Gross margin increased by 750 basis points over the fourth quarter of 2022 due to initial benefits from the transition of operations to Mexico For the first quarter of 2023, GAAP oper

      5/3/23 4:10:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm To Report First Quarter 2023 Financial Results

      Vapotherm, Inc. (NYSE:VAPO), ("Vapotherm" or the "Company"), today announced that it will release financial results for the first quarter of 2023 after the close of trading on Wednesday, May 3, 2023. Vapotherm's management team will host a conference call beginning at 4:30 p.m. ET to discuss the financial results and recent business developments. To listen to the conference call on your telephone, please dial +1 (888) 330-2391 for U.S. callers, or +1 (240) 789-2702 for international callers, approximately ten minutes prior to the start time and reference conference code 6585549. To listen to a live webcast, please visit the Investors section of the Vapotherm website at: http://investors.v

      4/27/23 4:30:00 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/24/24 7:04:57 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Amendment: SEC Form SC 13D/A filed by Vapotherm Inc.

      SC 13D/A - VAPOTHERM INC (0001253176) (Subject)

      9/20/24 10:32:59 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • SEC Form SC 13G filed by Vapotherm Inc.

      SC 13G - VAPOTHERM INC (0001253176) (Subject)

      7/18/24 7:24:17 PM ET
      $VAPO
      Medical/Dental Instruments
      Health Care

    $VAPO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Vapotherm downgraded by Canaccord Genuity with a new price target

      Canaccord Genuity downgraded Vapotherm from Buy to Hold and set a new price target of $5.00 from $12.00 previously

      5/6/22 7:28:09 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Vapotherm downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Vapotherm from Overweight to Underweight and set a new price target of $8.00 from $23.00 previously

      4/7/22 7:25:32 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care
    • Piper Sandler reiterated coverage on Vapotherm with a new price target

      Piper Sandler reiterated coverage of Vapotherm with a rating of Overweight and set a new price target of $36.00 from $39.00 previously

      2/25/21 7:36:13 AM ET
      $VAPO
      Medical/Dental Instruments
      Health Care